This survey sought to appraise the degree of consistency in the management of disappeared colorectal liver metastases (dCRLM) among liver surgeons in different countries.
Colorectal liver metastases (CRLM) account for half of the deaths secondary to colorectal cancer. Due to the high utilization of chemotherapy before surgery, some or all CRLM can disappear (dCRLM) but management of dCRLMs remains unclear.
Seven simulated scenarios of dCRLM were presented to experienced liver surgeons using an online platform. Treatment decisions were submitted and analysed using the multi-rater kappa method. The effect of the experience, complexity of scenarios, and location and number of dCRLM on treatment decision were analysed.
Sixty-seven liver surgeons from 25 countries completed the survey. There was no agreement about the therapeutic strategies of dCRLM in all scenarios (kappa 0.12, IQR 0.20–0.32). In scenarios with lower difficulty scores, surgeons tended to offer surgical resection for dCRLM alongside the visible CRLM (vCRLM), however, with poor agreement (kappa 0.32, IQR 0.19–0.51). No agreement was seen for clinical scenario in which all CRLM lesions disappeared (kappa 0.20).
There are clear inconsistencies in the management decisions of dCRLM. Better evidence is required to define optimal management strategies.
To read this article in full you will need to make a payment
Purchase one-time access:Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
One-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:Subscribe to HPB
Already a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
- Worldwide incidence of colorectal cancer.2020
- Global colorectal cancer burden in 2020 and projections to 2040.Transl Oncol. 2021; 14101174https://doi.org/10.1016/j.tranon.2021.101174
- Epidemiology and management of liver metastases from colorectal cancer.Ann Surg. 2006; 244: 254-259https://doi.org/10.1097/01.sla.0000217629.94941.cf
- Cause of death from liver metastases in colorectal cancer.Ann Surg Oncol. 2014; 21: 501-506https://doi.org/10.1245/s10434-013-3297-7
- Liver resection improves survival in colorectal cancer patients: causal-effects from population-level instrumental variable analysis.Ann Surg. 2019; 270: 692-700https://doi.org/10.1097/SLA.0000000000003485
- Recent advances in treatment for colorectal liver metastasis.Ann Gastroenterol Surg. 2018; 2: 167-175https://doi.org/10.1002/ags3.12071
- ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.Ann Oncol. 2016; 27: 1386-1422https://doi.org/10.1093/annonc/mdw235
- Expanding Criteria for Resectability of Colorectal Liver Metastases. Oncologist. 2008; 13: 51-64https://doi.org/10.1634/theoncologist.2007-0142
- Solitary colorectal liver metastasis.Arch Surg. 2006; 141: 460https://doi.org/10.1001/archsurg.141.5.460
- Surgical management of disappearing colorectal liver metastases.Br J Surg. 2013; 100: 1414-1420https://doi.org/10.1002/bjs.9213
- Management of disappearing colorectal liver metastases.Eur J Surg Oncol. 2016; 42: 1798-1805https://doi.org/10.1016/j.ejso.2016.05.005
- Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC intergroup trial 40983): a randomised controlled trial.Lancet. 2008; 371: 1007-1016https://doi.org/10.1016/S0140-6736(08)60455-9
- Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.Lancet Oncol. 2013; 14: 1208-1215https://doi.org/10.1016/S1470-2045(13)70447-9
- Management of disappearing colorectal liver metastases: an international survey.HPB. 2021; 23: 506-511https://doi.org/10.1016/j.hpb.2020.10.005
- Imaging in disappearing colorectal liver metastases and their accuracy: a systematic review.World J Surg Oncol. 2020; 18: 1-9https://doi.org/10.1186/s12957-020-02037-w
- Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases.Ann Surg Oncol. 2010; 17: 492-501https://doi.org/10.1245/s10434-009-0781-1
- Marking disappearing colorectal liver metastases after complete response to neoadjuvant chemotherapy via ct – a pilot study.Anticancer Res. 2019; 39: 3847-3854https://doi.org/10.21873/anticanres.13534
- Use of imaging to predict complete response of colorectal liver metastases after chemotherapy: MR imaging versus CT imaging.Radiology. 2017; 284: 423-431https://doi.org/10.1148/radiol.2017161619
- Complete response of colorectal liver metastases after chemotherapy: does it mean cure?.J Clin Oncol. 2006; 24: 3939-3945https://doi.org/10.1200/JCO.2006.05.8727
- Surgery-induced tumor growth in (metastatic) colorectal cancer.Surg Oncol. 2017; 26: 535-543https://doi.org/10.1016/j.suronc.2017.10.004
- Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases.Ann Surg. 2008; 248: 994-1003https://doi.org/10.1097/SLA.0b013e3181907fd9
- Utility of image guidance in the localization of disappearing colorectal liver metastases.J Gastrointest Surg. 2019; 23: 760-767https://doi.org/10.1007/s11605-019-04106-2
- Drop of total liver function in the interstages of the new associating liver partition and portal vein ligation for staged hepatectomy technique.Ann Surg. 2016; 263 (e33–4)https://doi.org/10.1097/SLA.0000000000001603
- Disappearing colorectal liver metastases after chemotherapy: should we Be concerned?.J Gastrointest Surg. 2010; 14: 1691-1700https://doi.org/10.1007/s11605-010-1348-y
- Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases.Ann Surg. 2009; 250: 935-942https://doi.org/10.1097/SLA.0b013e3181b0c6e4
- The dilemma of the disappeared colorectal liver metastasis: systematic review of reviews and evidence gap map.BJS Open. 2022; 6: 5-7https://doi.org/10.1093/bjsopen/zrac051
- Choices of therapeutic strategies for colorectal liver metastases among expert liver surgeons: a throw of the dice?.Ann Surg. 2020; 272: 715-722https://doi.org/10.1097/SLA.0000000000004331
- Comparison of cinematic rendering and computed tomography for speed and comprehension of surgical anatomy.JAMA Surg. 2019; : 1-7https://doi.org/10.1001/jamasurg.2019.1168
- Inequalities between multi-rater kappas.Adv Data Anal Classif. 2010; 4: 271-286https://doi.org/10.1007/s11634-010-0073-4
- Online kappa calculator [computer software].2008: 271 (228. Available at:)http://justusrandolph.net/kappa/Date accessed: December 16, 2021
- Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin.Ann Surg Oncol. 2007; 14: 3188-3194https://doi.org/10.1245/s10434-007-9482-9
- Colorectal liver metastases: an update on multidisciplinary approach.World J Hepatol. 2019; 11: 150-172https://doi.org/10.4254/wjh.v11.i2.150
Published online: January 27, 2023
Accepted: January 10, 2023
Received: August 30, 2022
Publication stageIn Press Corrected Proof
© 2023 International Hepato-Pancreato-Biliary Association Inc. Published by Elsevier Ltd. All rights reserved.